Viatris Inc. has acquired Aculys Pharma to enhance its presence in Japan's pharmaceutical market and reported strong financial results for Q3 2025.
Target Information
Viatris Inc. (NASDAQ: VTRS), a Global Healthcare company, is positioned to bridge the conventional gap between generics and branded medicines. Focused on enhancing healthcare access, Viatris provides high-quality medicines to nearly one billion patients worldwide annually. The company recently reported robust financial results for Q3 2025, reflecting consistent operational performance and strategic market execution.
During this quarter, Viatris highlighted advancements in its product pipeline, such as the submission of a New Drug Application (NDA) for its low-dose estrogen weekly patch and the acquisition of Aculys Pharma. This acquisition includes exclusive rights for the development and commercialization of pitolisant in Japan, along with Spydia® Nasal Spray in Japan and select Asia-Pacific markets.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Japan
The pharmaceutical industry in Japan is regarded as one of the largest and most advanced globally. It combines leading-edge research opportunities with a comprehensive regulatory environment. With its growi
Similar Deals
Viatris Inc.
invested in
Aculys Pharma, Inc.
in 2025
in a Other deal